09.00 – 10.15 New mechanistic insights in tumorigenesis (III)
Chairs: Vincenzo de Laurenzi, Giorgio Stassi
09.00 – 09.15 Alice Turdo: Role of Sam68 in modulating the tumorigenic and metastatic potential of breast Cancer Stem Cells
09.15 – 09.30 Simone Di Franco: p63 role in breast cancer progression
09.30 – 09.45 Annika Baude: LEDGF promotes DNA end resection and efficient DNA repair by homologous recombination
09.45 – 10.00 Antonella Di Cola: Nucleophosmin nucleolar localization depends on G-quadruplex binding at rDNA: implications for NPM1-associated acute myeloid leukemia
10.00 – 10.15 Tania Aaes-Jørgensen: Knockdown of HDGFRP2 impairs homologous recombination and CtIP recruitment to DNA double strand breaks
10.15 – 10.45 Coffee break
10.45 – 12.30 Tumor therapy I
Chairs: Michael Bots, Ricky Johnstone
10.45 – 11.00 Introduction by Ricky Johnstone
11.00 – 11.15 Ricky Johnstone: Identifying histone deacetylases important for tumor development, growth and survival through sophisticated gene knockdown techniques
11.15 – 11.30 Katrina J Falkenberg: A Genome-wide screen for novel genes involved in sensitisation to Histone Deacetylase Inhibitors
11.30 – 11.45 Selcuk Colak: Inhibition of HDACs sensitizes chemotherapeutic resistant colon Cancer Stem Cells
11.45 – 12.00 Michaela Waibel: Therapeutic activity of HDACi in a model of NOTCH1-driven T-ALL
12.00 – 12.15 Dagmar Kumls: Three dimensional melanoma treatment
12.15 – 12.30 Markus Rehm: Case-specific prediction of cell death responsiveness in malignant melanoma
13.00 – 14.30 Lunch
15.00 – 16.30 Tumor therapy II
Chairs: Michael Bots, Eric Eldering
15.00 – 15.15 Michael Bots: Targeting cancer stem cells as therapeutics in a mouse model of colon cancer
15.15 – 15-30 Anne Marie Ellegaard: Sunitinib and SU11652 induce permeabilization of the lysosomal membrane and revert multidrug resistance
15.30 – 15.45 Ana Carolina Martinez-Torres: CD47-mediated caspase-independent cell death: a new therapeutic tool to overcome apoptotic avoidance in chronic lymphocytic leukemia
15.45 – 16.00 Inge Verbrugge: Eradication of established mammary tumors using novel combinations of radiotherapy and immunomodulatory antibodies
16.00 – 16.15 Eric Eldering: Mapping the targets of Dasatinib in chronic lymphocytic leukemia; distinct roles for Abl and Btk in drug resistance and adhesion/migration
16.30 – 17.00 Coffee break
17.00 – 20.00 Sports (pétanque)
20.00 – 21.30 Dinner
21.30 – … Party